Phaseline

Targets › CIDEB

CIDEB (Lipid transferase CIDEB): drug programs, companies and trials

1 program from 1 company in 3 trials: 1 Phase 3, 1 Phase 2, 1 Phase 1; Gastroenterology, Metabolic and endocrine; next expected readout Aug 2027.

Lipid transferase specifically expressed in hepatocytes, which promotes unilocular lipid droplet formation by mediating lipid droplet fusion. Lipid droplet fusion promotes their enlargement, restricting lipolysis and favoring lipid storage. (UniProt, Q9UHD4)

Open in Phaseline: the race on CIDEB, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Regeneron PharmaceuticalsALN-CIDEB
CIDEB inhibitor
CIDEBPhase 3Metabolic Dysfunction-Associated Steatotic Liver Disease; Metabolic Dysfunction-Associated Steatohepatitis (MASH)Aug 2027

Conditions

Metabolic Dysfunction-Associated Steatotic Liver Disease (2) Metabolic Dysfunction-Associated Steatohepatitis (MASH) (1)

Modalities

small molecule (1)

Companies

Regeneron Pharmaceuticals (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.